Cargando…
Physical and chemical stability of Taxotere(®) (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage
A one-vial formulation of the chemotherapy agent Taxotere(®) (docetaxel) is likely to be commercially available in some countries in 2010. Through control of two significant potential risk factors for crystallization—intervention into the infusion bag (by using a one-step technique) and temperature...
Autores principales: | Hart, M, Acott, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234020/ https://www.ncbi.nlm.nih.gov/pubmed/22276044 http://dx.doi.org/10.3332/ecancer.2010.202 |
Ejemplares similares
-
Interaction of Docetaxel (“Taxotere”) with Human P‐Glycoprotein
por: Shirakawa, Katsuro, et al.
Publicado: (1999) -
Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001) -
Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
por: Verweij, J.
Publicado: (1994) -
Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005) -
S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.
por: Hennequin, C., et al.
Publicado: (1995)